United States Iron-Deficiency Anemia Therapy Market

United States Iron-Deficiency Anemia Therapy Market Summary

As per Transpire Insight Analysis the United States Iron-Deficiency Anemia Therapy Market size is estimated at USD 2128.6 Million in 2025 and is anticipated to reach USD 3638.5 Million by 2033, growing at a CAGR of 7.15% from 2026 to 2033.

The United States Iron-Deficiency Anemia Therapy Market really supports healthcare providers as they work to restore iron levels when deficiency leads to fatigue, lower oxygen-carrying ability, and overall impaired daily life or clinical functioning . In day to day use, treatment can look like oral iron products for routine deficiencies, yet for some patients intravenous therapy becomes the go-to, especially when a quicker replenishment is needed, or when oral treatment isn’t well tolerated. Over the past three to five years , you can see a shift toward more practical and clinically focused approaches, with an emphasis on intravenous formulations that get used when oral therapy ends up being insufficient. The COVID-19 disruptions also highlighted weak spots in healthcare supply chains, and that pushed providers to lock in dependable treatment routes, often with outpatient administration .

Market momentum now seems tied to a more careful therapy-sequencing mindset, where clinicians choose the option based on how severe the deficiency is, how well iron can actually be absorbed, how the patient tolerates it, and how fast correction is required. That angle then helps expand the reach of intravenous products, and it opens up revenue chances for manufacturers that can deliver distinct formulations, easier administration, and dependable supply .

United States Iron-Deficiency Anemia Therapy Market Size & Forecast:

• United States Iron-Deficiency Anemia Therapy Market Size 2025: USD 2128.6 Million
• Expected Market Value 2033: USD 3638.5 Million
• Forecast CAGR: 7.15%
• Key Profile: CSL Vifor, Daiichi Sankyo, Pharmacosmos, American Regent, Sanofi, Pfizer Inc., Fresenius Kabi, AMAG Pharmaceuticals, Shield Therapeutics, GSK plc, Viatris Inc., Teva Pharmaceutical Industries, AbbVie Inc., Johnson & Johnson, Novartis AG.

Key Market Insights

• Dominant region: Basically, The United States keeps leading North America’s therapy picture, with North America accounting for about 36.6% of the global market share in 2022, and you can see it quite clearly.
• Fastest-growing region: In the U.S. specifically, appetite for these treatments is widening, not only in outpatient settings, but also along home-care routes during the 2023–2030 forecast span, and that shift looks consistent.
• Leading segment: Parenteral iron therapy brought in a big 61.51% share of U.S. revenue in 2022, mainly because replenishing iron quickly is a frequent necessity.
• Second-largest segment: Oral iron therapy is still the second-largest treatment category , though newer formulations are making it more competitive and giving it better staying power.
• Fastest-growing segment: Oral iron therapy is projected to be the fastest-growing segment through 2030, which lines up with the added attention on tolerability and everyday convenience.
• Dominant application: Obstetrics and gynecology shows up as a leading therapy area, while in the U.S. specialized care is expanding care plans across a bunch of anemia-related situations.
• Fastest-growing application: Obstetrics and gynecology is expected to grow the quickest , at 10.53% CAGR over 2024–2032, which is pretty notable.
• Leading end-user segment: Hospitals remain the top end-user route, helped by infusion infrastructure plus more involved cases that really need monitored parenteral treatment.
• Fastest-growing end-user category: Home healthcare is starting to ramp up as a quicker channel, since care pathways are gradually moving toward easier outpatient and at-home models.

What are the Key Drivers, Restraints, and Opportunities in the United States Iron-Deficiency Anemia Therapy Market?

The market is getting shaped by this kind of treatment shift toward formulations that ease administration burden , while also covering people who fail or just can’t tolerate standard oral iron. Parenteral therapy still accounted for 61.51% of U.S. revenue in 2022 , yet oral therapy is expected to expand faster through 2030 , mainly as differentiated formulations get better on tolerability and prescribing flexibility.

The main brake on adoption is reimbursement coupled with treatment access complexity. Specialty products have to go up against inexpensive conventional iron and still show clinical plus economic value. Shield’s U.S. footprint shows the commercial pushback: roughly 25% of Accrufer prescriptions stayed consignment-based in H1 2025 , even though that was down from around 44% in H1 2024. And from what Transpire Insight saw in regional procurement announcements and launch calendars, the supply chain concentration is still the biggest execution risk, no surprise there.

The best opening is more personalized treatment selection, using lab inputs together with digital decision support. A 2024 deep learning study , based on 30,603 patient records, reported 0.83 accuracy and 0.89 AUC ROC when forecasting iron-deficiency anemia three to six months ahead of the conventional diagnosis. If wider EHR integration happens sooner, it could spot eligible patients earlier and then direct the right situations toward oral or intravenous approaches.

What Has the Impact of Artificial Intelligence Been on the United States Iron-Deficiency Anemia Therapy Market?

AI is starting to sort of reshape anemia management by taking regular lab results and turning them into earlier “hey something’s off” signals. In everyday clinical workflows, algorithms can quietly flag abnormal hemoglobin , ferritin, transferrin saturation, plus the red-cell indices, so the care team can quickly sort of prioritize who needs confirmatory testing and a treatment review. There’s a 2024 deep learning study that trained on 30,603 longitudinal outpatient records and it predicted iron-deficiency anemia three to six months before the traditional diagnosis, reporting about 0.83 accuracy and a 0.89 area under the ROC curve. 

Beyond just detection, machine learning can also back demand forecasting by stitching together historical prescriptions, lab movement over time, specialty-clinic activity, and seasonal patient volumes, so infusion centers can plan staffing and inventory in a more ordered way. Digital screening approaches might also nudge treatment toward earlier identification, which could reduce those avoidable delays between finding a lab abnormality and actually starting therapy. Still, the operational wins are not that straightforward, because fragmented EHR systems, inconsistent lab data, integration costs, and limited prospective validation keep getting in the way. At the moment, the evidence shows technical feasibility more clearly than broad U.S. commercial deployment. If validation keeps getting better, AI assisted triage could improve sequencing of treatment and support resource allocation across oral, parenteral, and outpatient routes.

Key Market Trends

• In 2021, Injectafer sorta expanded its positioning with pediatric approval, plus a single-dose option, which reinforced convenience inside intravenous treatment pathways.
• In 2024, U.S. obstetrics and gynecology generated USD 139.50 million so maternal care became the biggest therapy area revenue pool.
• During 2025, three generic iron-sucrose approvals sort of upped the competitive pressure on established intravenous products, and also widened what hospitals can procure.
• In 2025, CSL Vifor said it kept seeing sustained volume growth for FERINJECT while it was preparing more than 30 planned iron and nephrology launches.
• In September 2025, Shield got FDA Priority Review for pediatric Accrufer, that extends its oral-treatment opportunity toward adolescents.
• During 2025, Accrufer prescriptions , and revenue had already accelerated, with 2024 prescriptions up 95%, and revenue up 153%.
• U.S. research is increasingly backing earlier computational detection, with a 30,603 patient model predicting iron-deficiency anemia months before conventional diagnosis.
• Pharmacosmos is now pushing Monoferric clinical development into symptomatic heart failure via a Phase 3 study, broadening the intravenous iron evidence.
• Home-care treatment is also picking up strategic value, with the U.S. home-care segment expected to grow at 9.34% CAGR through 2032.
• Oral therapy innovation is still commercially relevant, as newer formulations tackle gastrointestinal tolerability, absorption, adherence, and that convenience type of limitation.

United States Iron-Deficiency Anemia Therapy Market Segmentation

By Therapy Type : 

Oral iron supplements are still really widely used, due to low overall treatment cost, easy to give out, and just general broad availability via both retail and hospital pharmacies . Meanwhile, intravenous iron therapy has, sort of, taken a firmer place for people who need faster iron replenishment , or who can not tolerate oral treatment very well. Ferric carboxymaltose and iron sucrose are commonly used for hospital-based care, in particular for patients with chronic kidney disease, heavy blood loss, or poor iron absorption problems. Blood transfusion stays mostly reserved for the most severe anemia where rapid correction is needed , and erythropoiesis-stimulating agents are usually used for selected patients with chronic kidney disease and other serious medical situations.

Combination therapy also comes into play , when the treatment plan needs iron replacement together with nutritional support or other interventions. Nutritional therapy is still quite helpful for patients with only mild deficiency, especially when it is connected to insufficient dietary iron intake . Iron dextran keeps being used for some patients who require parenteral iron, but newer parenteral formulations provide more convenient dosing. Ultimately product selection will hinge on how severe the anemia is, how well the patient tolerates treatment, whether administration is in a hospital or elsewhere, the patient’s broader condition, and reimbursement factors.

By Route of Administration : 

Oral administration stays kind of convenient for routine care, because tablets and capsules need only limited clinical infrastructure. Meanwhile, intravenous administration has gained momentum as hospitals and specialty clinics handle people who need faster iron replenishment. Injectable treatment is often used in selected clinical scenes where oral therapy cannot really correct things enough. Infusion therapy, too, helps with higher-dose iron delivery, but only under medical supervision.

Hospital administration still matters a lot for patients with severe deficiency, chronic kidney disease, cancer, or when medical needs are more complex. Homecare administration is starting to attract attention, as healthcare providers try to offer a more convenient treatment setting and reduce the amount of facility use. Specialty clinics are another workable path for monitored iron therapy, especially when patients need repeated sessions.

By End User : 

Hospitals are a big treatment place because they handle severe anemia and also those patients who have many underlying conditions at once, you know… Dialysis centers create a lot of therapy use too, since chronic kidney disease commonly needs consistent iron management, almost like routine care. Specialty clinics help people who still need monitored infusion treatment but without a full hospital stay, which can feel less disruptive. Academic medical centers and research institutes add value by running clinical studies , evaluating therapies, and working on new improved therapy methods, step by step.

Home healthcare is getting more and more important as treatment delivery keeps moving away from only one location. Ambulatory surgical centers can also fit anemia management around planned procedures, especially if preoperative correction boosts treatment readiness before the main event. Picking the end-user option depends on disease intensity, how often treatment shows up, whether infusion is required, the level of clinical monitoring, and how reimbursement is set up. Shifts in outpatient care will back wider adoption of specialty clinics and home based services.

By Patient Type : 

Adults can be seen as a fairly wide treatment population, since iron deficiency might show up not only from food gaps but also from long term blood loss, gastrointestinal issues, and other medical causes, it’s kind of a mixed picture. Pregnant women need careful iron management too because pregnancy cranks up iron requirements pretty fast and anemia may influence maternal and fetal outcomes. Women who have menorrhagia are also an essential group because ongoing bleeding can gradually deplete iron stores over time, even if it doesn’t look dramatic at first. Pediatric patients, on the other hand, require treatment that matches their age and dosing has to be handled very carefully, no shortcuts.

For geriatric patients, anemia treatment is often paired with dealing with chronic conditions, plus medication related complications that can pop up. In CKD, many patients tend to get intravenous iron as part of larger anemia programs. Cancer patients can also experience iron deficiency from chronic disease itself, from treatment effects, from blood loss, or from nutrition related problems. In the end, what you choose for each patient will hinge on their iron status, the main underlying condition, age, how severe things are, how well they tolerate therapy, and how they respond to earlier treatment.

By Distribution Channel : 

Hospital pharmacies are still kind of crucial for intravenous products, urgent care, and medicines delivered inside the hospital environment, even when other channels exist. Meanwhile retail pharmacies help with broad access to oral iron supplements and other basic treatments for everyday use, which is sort of the usual thing people think of. Then specialty pharmacies take care of certain products that need extra patient support, prescription administration, and steady coordination with clinicians, not just “hand it over and go”. Wholesalers, on the other hand, link manufacturers up with hospitals, pharmacies, clinics, and other health purchasers so the supply chain doesn’t get stuck.

Also, government supply and direct tender pathways support buying across public healthcare facilities and various institutional programs, so procurement can keep moving. Institutional sales let manufacturers talk about bigger, higher-volume agreements with hospitals, healthcare networks, and treatment centers. Online pharmacies add yet another purchasing option, especially for oral therapies and refills, which can be convenient. In the end distribution plans will depend on the product type, storage needs, prescription requirements reimbursement, procurement contracts, and the actual care setting where the therapy gets used.

What are the Key Use Cases Driving the United States Iron-Deficiency Anemia Therapy Market?

Hospitals are still, the main use case, especially for intravenous iron therapy for patients who need rapid replenishment of iron. The people in hospital procurement, the nephrology departments, and the surgical units, go after these therapies to handle anemia tied to chronic kidney disease, blood loss, and sometimes preoperative needs. Clinical protocols plus reimbursement kind of keep the whole thing going steadily in institutions.

Then you have specialty clinics and dialysis centers, which are becoming more common. Specialty clinics tend to offer monitored infusion treatment, but without the prolonged hospital stay, if anything it feels more efficient. Dialysis centers also lean on iron therapies as part of ongoing chronic kidney disease care. In those environments the repeat sessions make sense, and there’s coordinated patient monitoring throughout.

Home healthcare and outpatient infusion services are showing up as emerging opportunities. When decentralized care is used more, it can move a few selected iron treatments away from hospitals. Digital monitoring, remote follow up, and payer-supported outpatient models should boost adoption for the right patients during the forecast period.

Which Regions are Driving the United States Iron-Deficiency Anemia Therapy Market Growth?

The Northeast, it kind of represents a major U.S. demand center, even if a clean standalone regional percentage is not really publicly disclosed. In practice, dense hospital networks, academic medical centers, specialty clinics, and a fairly solid reimbursement framework help drive broad use of oral as well as intravenous therapies. Around Boston, New York, Philadelphia and other long established healthcare hubs, pharmaceutical research stays active, and that backs clinical adoption while also improving product evaluation. Overall, leadership is expected to keep being supported through 2026–2033 by concentrated specialist care, advanced diagnostics, and ongoing investment in complex disease management.

The South has a structurally different growth base, with demand spread across big hospital systems, dialysis centers, outpatient settings, plus healthcare networks that are still growing quickly. Economic resilience and continued spending on healthcare infrastructure sustain recurring treatment volumes across chronic kidney disease, women's health, and other anemia linked conditions. With large patient populations, there are dependable purchasing needs for both oral offerings and parenteral therapies. So this region looks more like a steady revenue contributor, not just a market that depends on a small number of specialist centers.

The West is basically positioned as a quicker regional chance, built on technology-driven healthcare systems , more outpatient care growth, and the broader use of digital patient management. Lately, remote monitoring improvements and decentralized treatment models could let some anemia services move toward specialty clinics and even homecare type settings. In that kind of scene, product suppliers that offer convenient dosing, digital help, and flexible distribution approaches can reach these emerging routes with more strength. So from 2026–2033, the region should pull in new entrants who want momentum via outpatient innovation, tech-enabled care, and a more distinct way of delivering treatment.

Who are the Key Players in the United States Iron-Deficiency Anemia Therapy Market and How Do They Compete?

Competition in the U.S. therapy market feels kinda concentrated around established intravenous and oral iron brands, yet generic products are still pressuring prices in a steady way. The main battleground tends to be dosing convenience, clinical proof, reimbursement access, where treatment actually happens, and whether providers can cut down repeat visits, not just the initial administration. In the broader market, parenteral therapy held the biggest revenue slice , but oral therapy is expected to grow quicker, so there’s more room for both the old guard manufacturers and for specialized entrants that come in with a narrower angle.

Daiichi Sankyo fights with Injectafer , it uses ferric carboxymaltose and pushes higher-dose administration to back rapid iron replacement. In 2023 FDA approval for heart-failure patients widened the clinical use, so it added a differentiated indication beyond routine deficiency treatment. CSL Vifor leans into intravenous iron via products like Venofer and Ferinject, and they’ve built up extensive clinical exposure, plus provider familiarity, which helps with hospital and dialysis procurement. Venofer, in particular, has over 38 million patient-years of exposure and it stays more specifically positioned for CKD-associated iron deficiency.

Pharmacosmos differentiates with Monoferric, this ferric derisomaltose formulation is kind of tuned for higher-dose iron replacement and fewer treatment appointments, you know. Then Shield Therapeutics goes with a more niche oral angle, using Accrufer and ferric maltol to reach people who need prescription oral iron, and there was an FDA expansion for patients aged 10 years and older in 2025. Meanwhile Sandoz and Viatris push a cost-focused plan via generic iron products, which ramps up procurement options and puts pressure on branded intravenous therapies, a bit more than before.

Company List

• CSL Vifor
• Daiichi Sankyo
• Pharmacosmos
• American Regent
• Sanofi
• Pfizer Inc.
• Fresenius Kabi
• AMAG Pharmaceuticals
• Shield Therapeutics
• GSK plc
• Viatris Inc.
• Teva Pharmaceutical Industries
• AbbVie Inc.
• Johnson & Johnson
• Novartis AG 

Recent Development News

In August 2025, Viatris received U.S. FDA approval for its first generic iron sucrose injection for iron-deficiency anemia in patients with chronic kidney disease. The approval introduced a lower-cost intravenous alternative to Venofer and strengthened competition in a high-volume treatment category.

Source: https://www.prnewswire.com/

In September 2025, Sandoz launched generic iron sucrose injection across the United States following FDA approval. The launch expanded affordable intravenous iron supply and added another supplier to the U.S. treatment market, with Sandoz developing the product in partnership with RAFARM.

Source: https://www.businesswire.com/

What Strategic Insights Define the Future of the United States Iron-Deficiency Anemia Therapy Market?

Over the next five to seven years, the U.S. iron-deficiency anemia therapy market will likely move toward more individualized treatment, with therapy selection getting shaped more and more by disease severity, iron status, how well patients tolerate treatment, and also the care setting. The main undercurrent is that we will stop treating anemia only in a sort of episodic way, and instead lean toward earlier diagnosis, plus a more coordinated approach to managing the patient across hospitals, specialty clinics, and outpatient services.

One hidden risk is market concentration in the intravenous iron supply side, so if there are manufacturing disruptions or procurement shifts, availability and pricing could change very quickly. At the same time there is an emerging opportunity in AI-supported screening, that can catch iron deficiency earlier, using routine laboratory records, and it can help build a pathway to treatment before anemia becomes clinically severe. Market participants should put money into integrated diagnostic-to-treatment platforms that tie lab alerts to clinical decision support and also make iron delivery easier. With that kind of positioning you can strengthen patient capture, lower treatment delays, and offer a clearer, more differentiated value than just product pricing alone.

United States Iron-Deficiency Anemia Therapy Market Report Segmentation

By Therapy Type

• Oral Iron Supplements
• Intravenous Iron Therapy
• Blood Transfusion
• Erythropoiesis-Stimulating Agents
• Combination Therapy
• Nutritional Therapy
• Iron Dextran
• Ferric Carboxymaltose
• Iron Sucrose

By Route of Administration

• Oral
• Intravenous
• Injectable
• Hospital Administration
• Homecare Administration
• Infusion Therapy
• Specialty Clinics
• Combination Route

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Dialysis Centers
• Home Healthcare
• Academic Medical Centers
• Research Institutes

By Patient Type

• Adults
• Pediatric Patients
• Pregnant Women
• Geriatric Patients
• CKD Patients
• Cancer Patients
• Women with Menorrhagia

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• Government Supply
• Institutional Sales
• Direct Tender
• Wholesalers